Recent News

November 21, 2018 at 7:00 AM EST

Summary Toggle Proteostasis Therapeutics to Participate in Upcoming Investor Conferences

BOSTON , Nov. 21, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
October 23, 2018 at 7:25 PM EDT

Summary Toggle Proteostasis Therapeutics Prices Public Offering of Common Stock

BOSTON , Oct. 23, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
October 22, 2018 at 4:01 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

BOSTON , Oct. 22, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
October 17, 2018 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients

PTI-801 and PTI-808 Dose Response Observed Across All Cohorts and Statistical Significance Achieved on All Endpoints Mean Change from Placebo of up to +8% in ppFEV1 and -13mM in Sweat Chloride Observed at Third Dose Level; Fourth and Highest Dosing Cohort Ongoing Screening of First Triplet
September 27, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference

BOSTON , Sept. 27, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
June 25, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Added to the Russell 3000® Index

BOSTON , June 25, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
June 6, 2018 at 4:05 PM EDT

Summary Toggle Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

Results Show Statistically Significant Improvement in Sweat Chloride, Body Mass Index, Weight and Blood Glucose Treatment Led to a Statistically Significant Improvement in Blood Glucose Levels and the Reversal of Hyperglycemia in a Diabetic CF Subpopulation Improvement in FEV1 Observed Across All
June 1, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

BOSTON , June 1, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
May 31, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

BOSTON , May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
May 8, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment BRIGHTON, Mass. , May 8, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking